Cancer Cell Signaling

癌细胞信号传递计划(SIG)由致力于提供基本的 细胞内和细胞间控制肿瘤细胞增殖、偏头痛、 以及了解如何利用这些信息来改进诊断、预防、 以及癌症的治疗。项目成员利用这些基本知识来研究肿瘤细胞 使用体外细胞培养模型和体内实验，对微环境和药物治疗的反应 基因工程小鼠模型和单个癌症的异种移植模型。研究细胞信号转导 临床前癌症模型的背景提供了细胞信号向实际背景的相关翻译 进行治疗干预。 SIG由David Brautigan博士和J.Thomas Parsons博士领导，他们两人都有丰富的经验 在细胞信号研究以及计划和行政领导方面。项目负责人催化 通过组织务虚会促进新的和创新的方法，分配信号研究的进展 “迷你”试点助学金，鼓励开发新理念和新技术，重点是利用 癌症中心共享资源，为癌症的整体智力环境做出贡献 中心通过参加研讨会、期刊俱乐部、进行中的研究以及本科生和研究生 教育。 SIG的22个成员的研究围绕三个主题组织：(1)理解基础 癌细胞信号网络的特性；(2)识别控制细胞对 微环境；以及(3)定义体内系统以研究信号网络和测试临床前 癌症治疗的治疗策略。该项目的外部资金总额超过1800万美元， 其中包括来自国家癌症研究所(NCI)的250万美元。在过去的五年里，SIG成员 发表了504篇与计划相关的论文，其中33%是计划间的，13%是计划内的 程序化的。SIG的未来目标是促进发现科学，专注于复杂的 信号网络，肿瘤如何对微环境作出反应，以及肿瘤如何进化以生存。 癌症疗法。SIG将局限于利用优秀的共享资源，促进合作 和创新。最后，SIG将在该计划和癌症中心内聘请肿瘤学家和外科医生 抓住机会将信令网络的信息转化为临床应用。

The Cancer Cell Signaling Program (SIG) is comprised of invesfigators dedicated to providing fundamental knowledge of the intra- and inter-cellular signaling pathways that control tumor cell proliferafion, migrafion, and survival and to understanding how this informafion can be used to improve the diagnosis, prevention, and treatment of cancer. Program members utilize this fundamental knowledge to study tumor cell responses to the microenvironment and to drug treatments, using in vitro cell culture models and in vivo genetically engineered mouse models and xenograft models of individual cancers. Studying cell signaling in the context of pre-clinical cancer models provides relevant translation of cell signaling to the practical context of therapeutic intervention. SIG is led by David Brautigan, PhD and J. Thomas Parsons, PhD both of whom have extensive experience in cell signaling research and programmatic and administrative leadership. The Program leaders catalyze advances in signaling research by organizing retreats to foster new and innovative approaches, dispense "mini" pilot grants to stimulate the development of new ideas and technologies with an emphasis on using Cancer Center Shared Resources, and contribute to the overall intellectual environment of the Cancer Center by participating in seminars, journal clubs, research in progress and graduate and postgraduate education. The research of the 22 members of SIG is organized around three themes: (1) understanding fundamental properties of cancer cell signaling networks; (2) identifying pathways that govern cell responses to the microenvironment; and (3) defining in vivo systems to study signaling networks and test preclinical therapeufic strategies for cancer treatment. Total extramural funding for the Program exceeds $18 million, including $2.5 million from the Nafional Cancer Institute (NCI). Over the past five years, SIG Members have published 504 Program-relevant papers of which 33% were inter-Programmatic and 13% were intra Programmatic. The future goals of SIG are to foster discovery science focused on the complex integrafion of signaling networks, on how tumors respond to the microenvironment, and how tumors evolve to survive anti cancer therapies. SIG will confinue to utilize the outstanding Shared Resources and promote collaboration and innovation. Finally, SIG will engage oncologists and surgeons within the program and Cancer Center to seize opportunities for translation of information on signaling networks to clinical applications.